Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events

Subsequent Events
9 Months Ended
Sep. 30, 2018
Subsequent Events [Abstract]  
Subsequent Events

13. Subsequent Events  

Following first dosing of IV sulopenem in the Phase 3 cUTI trial, the Company recorded a liability of $7,500 payable to Pfizer in the fourth quarter under the terms of its license agreement with Pfizer.